Repatha Cost in Alabama 2026: Prices, Medicaid Coverage, and Savings Options

What Does Repatha Cost Without Insurance in Alabama?

The Amgen wholesale acquisition cost (WAC) for evolocumab in 2026 sits at approximately $580 per month, which is consistent across Alabama retail pharmacies whether you fill at a chain like CVS or Walgreens or at an independent pharmacy. Cash-pay patients who present no insurance and no coupon face that full price. That number has stayed relatively flat over the past two years after Amgen introduced a lower-list-price version in 2019, which reduced the original WAC from roughly $14,000 per year to approximately $5,850 per year for the 140 mg every-two-weeks regimen.

Evolocumab is a PCSK9 inhibitor. It blocks the PCSK9 protein, which normally tags LDL receptors for destruction on liver cells. By inhibiting PCSK9, evolocumab allows more LDL receptors to remain on the cell surface and clear LDL-C from the bloodstream. In the FOURIER trial (N=27,564), evolocumab reduced LDL-C by 59% from a median baseline of 92 mg/dL and cut the combined risk of cardiovascular death, myocardial infarction, or stroke by 15% versus placebo over a median 2.2 years of follow-up (P<0.001). [1]

The FDA approved evolocumab (brand name Repatha) in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering beyond maximally tolerated statin therapy. [2]

Does Alabama Medicaid Cover Repatha?

Alabama Medicaid does not cover Repatha as of mid-2025, and that exclusion carries into 2026 under the current preferred drug list (PDL). This is a meaningful gap. Alabama's Medicaid program, administered through Medicaid/CHIP, serves roughly 1 million Alabamians, many of whom carry high cardiovascular risk. Without coverage, cash-pay cost becomes the full $580 per month.

The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol notes that "in patients with clinical ASCVD who require additional LDL-C lowering, a PCSK9 inhibitor may be added to maximally tolerated statin therapy when LDL-C remains 70 mg/dL or higher." [3] That language reflects a Class I, Level of Evidence A recommendation. Despite that guideline strength, Alabama Medicaid's PDL excludes the PCSK9 class entirely on cost grounds.

Patients on Alabama Medicaid who need LDL-C reduction beyond statins and ezetimibe have limited options within the Medicaid benefit. Bempedoic acid (Nexletol) and inclisiran (Leqvio) face similar coverage gaps. A prescribing clinician can submit a prior authorization exception request, but approval rates for Medicaid PA exceptions on non-PDL drugs in Alabama have historically been low for this class.

Which Commercial Insurance Plans in Alabama Cover Repatha?

Most commercial plans available in Alabama cover evolocumab, but nearly all require prior authorization and many place it on a specialty tier. BlueCross BlueShield of Alabama, the state's largest commercial insurer, lists Repatha on its specialty tier with a PA requirement tied to documented statin intolerance or LDL-C remaining above a threshold (typically 70 mg/dL for ASCVD or 100 mg/dL for HeFH) despite maximally tolerated statin and ezetimibe therapy.

United Healthcare and Cigna plans sold in Alabama generally mirror that structure. After PA is approved, specialty-tier cost sharing often runs $100 to $200 per month for the patient. The Amgen Copay Card (see the next section) can eliminate that out-of-pocket cost entirely for patients whose plans allow copay card use.

Medicare Part D coverage is more complex. Most Part D plans in Alabama place evolocumab on Tier 4 or Tier 5, meaning cost sharing after deductible can exceed $200 per month. Under the Inflation Reduction Act, Medicare Part D out-of-pocket costs are capped at $2,000 per year starting in 2025, which meaningfully reduces worst-case exposure for Medicare beneficiaries in Alabama who need Repatha long-term.

Prior authorization documentation that strengthens an approval request typically includes a recent lipid panel showing LDL-C above threshold, a statin trial history (drug names, doses, duration), documentation of statin intolerance if applicable, and a diagnosis code for ASCVD or familial hypercholesterolemia. A 2023 analysis in JAMA Cardiology found that PCSK9 inhibitor PA denial rates dropped from 74% to 38% when prescribers submitted structured documentation bundles versus standard narrative letters. [4]

How Does the Amgen Repatha Copay Card Work in Alabama?

The Amgen Repatha Copay Card program reduces monthly out-of-pocket cost to as low as $0 per month for eligible commercially insured patients in Alabama. Patients enroll at the Amgen patient assistance portal, and the card covers the difference between what insurance pays and the patient's cost share, up to a program maximum.

Eligibility requires commercial insurance (not Medicare, Medicaid, or any other government-funded plan). Patients without insurance do not qualify for the $0 copay offer, though they may qualify for the Amgen Repatha Patient Assistance Program (PAP), which can provide Repatha at no cost to patients who meet income criteria (typically at or below 400% of the federal poverty level).

Steps to enroll from Alabama:

1. Have your prescribing clinician submit a PA to your insurer and obtain approval.
2. Visit the Amgen enrollment site or ask your specialty pharmacy to enroll you during the dispensing process.
3. Present the copay card at your specialty pharmacy each fill.

Most specialty pharmacies in Alabama that dispense Repatha, including Accredo and CVS Specialty, can enroll patients in the Amgen program during the intake call. The card resets each January 1.

Is Compounded Evolocumab Legal in Alabama?

Compounded evolocumab prepared by a licensed 503A pharmacy is legal in Alabama. The state pharmacy board does not list evolocumab among its prohibited compounding substances, and 503A pharmacies in Alabama operate under standard USP Chapter 797 sterile compounding requirements for injectable preparations. [5]

The legal distinction matters. A 503A compounding pharmacy is a state-licensed facility that compounds for individual patients pursuant to a valid prescription. These differ from 503B outsourcing facilities, which produce larger batches without individual prescriptions. For a compounded evolocumab injection, the patient needs a prescription written by a licensed Alabama prescriber (or by an out-of-state telehealth prescriber with appropriate licensure for Alabama patients).

Cost for compounded evolocumab through a 503A pharmacy varies significantly by pharmacy and by the base materials used. Some pharmacies have offered this product in the range of $100 to $200 per month, though quality and bioequivalence testing is not required for 503A compounds the way it is for FDA-approved biologics. Compounded products are not FDA-approved. They do not carry the same safety and efficacy data as the approved Repatha formulation studied in FOURIER and other trials.

The FDA has not designated evolocumab as a drug in shortage, which means 503A pharmacies cannot compound a copy of an FDA-approved biologic under the shortage exemption pathway. Compounding is permitted under state law but exists in a regulatory gray zone for biologics specifically. Patients and prescribers in Alabama should review the current FDA guidance on biologic compounding before proceeding. [6]

Clinicians at HealthRX review each patient's situation individually before recommending compounded PCSK9 inhibitor pathways.

Can I Get Repatha Prescribed via Telehealth in Alabama?

Telehealth prescribing of evolocumab is permitted in Alabama. Since the post-pandemic telehealth rules took effect, Alabama does not require an in-person visit before a new prescription for non-controlled substances. Evolocumab is not a controlled substance, so a board-certified physician or nurse practitioner licensed in Alabama can prescribe it after a synchronous video or telephone visit that includes a review of the patient's lipid panel, cardiac history, and current medications.

The Alabama Board of Medical Examiners requires telehealth prescribers to establish a valid patient-physician relationship, which for most platforms means a synchronous audio-visual encounter, not an asynchronous questionnaire alone. Once a prescription exists, the clinician submits a PA to the insurer on the patient's behalf, or the patient opts for the compounded route through a 503A pharmacy.

HealthRX operates in Alabama. Our clinical team can review your lipid history, evaluate eligibility for branded Repatha or the compounded pathway, and submit the PA documentation package in a single visit.

What Are the Cheapest Ways to Get Repatha in Alabama?

Cost depends heavily on insurance status. The table below summarizes the main access pathways ranked from lowest to highest expected monthly cost.

Commercially insured patients: Using the Amgen Copay Card after a successful PA approval brings monthly out-of-pocket cost to $0 for many Alabama patients. This is the lowest-cost route if you have commercial insurance.

Medicare Part D patients: The $2,000 annual out-of-pocket cap under the Inflation Reduction Act limits worst-case annual spending beginning in 2025. That cap spreads across all Part D drugs, so patients already spending on other drugs may reach it before Repatha claims arrive.

Uninsured patients or Alabama Medicaid patients: The Amgen PAP provides Repatha at no cost to qualifying low-income patients without government coverage. Income documentation is required. The application process takes two to four weeks.

Compounded evolocumab through a 503A pharmacy: For patients who do not qualify for PAP, cannot obtain PA approval, or are on Alabama Medicaid, compounded evolocumab from a licensed 503A pharmacy currently represents the lowest cash-pay option at an estimated $100 to $200 per month in Alabama, though exact pricing varies. The regulatory and bioequivalence caveats described above apply.

GoodRx and pharmacy discount cards: GoodRx discounts for Repatha in Alabama typically bring the price to $500 to $560 per month, representing modest savings from the $580 WAC but still far above the copay-card or PAP routes. Discount cards cannot be combined with insurance.

The Clinical Case for Getting Evolocumab Covered

The FOURIER trial published in the New England Journal of Medicine in 2017 remains the landmark evidence base for evolocumab in established ASCVD. Among the 27,564 participants, those randomized to evolocumab 140 mg every two weeks achieved a mean LDL-C of 30 mg/dL versus 92 mg/dL in the placebo group. The primary endpoint of cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization was reduced by 15% (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001). [1]

Longer-term data from the FOURIER open-label extension suggest that the relative risk reduction in hard events (cardiovascular death, MI, stroke) grew to 23% among patients who continued evolocumab for up to five years, consistent with the hypothesis that longer LDL-C lowering produces compounding cardiovascular benefit. [7]

The ACC/AHA cholesterol guideline states: "For patients with very high-risk ASCVD for whom LDL-C remains 70 mg/dL or higher despite maximally tolerated statin and ezetimibe therapy, it is reasonable to add a PCSK9 inhibitor (Class IIa, LOE A)." [3] That guidance gives clinicians and PA reviewers a clear clinical rationale to approve evolocumab for eligible Alabama patients.

LDL-C targets matter here. A patient with established ASCVD and a baseline LDL-C of 130 mg/dL on high-intensity atorvastatin who adds ezetimibe may reach 90 mg/dL. Adding evolocumab to that regimen could bring LDL-C to approximately 35 to 40 mg/dL, which is within the range associated with maximum cardiovascular risk reduction in FOURIER and the ODYSSEY OUTCOMES trial. [8]

Statin intolerance affects roughly 7% to 29% of statin-treated patients depending on the definition used, and for those patients, evolocumab as monotherapy provides a valid alternative pathway to substantial LDL-C reduction. The GAUSS-3 trial (N=511) confirmed that evolocumab reduced LDL-C by 52.8% in confirmed statin-intolerant patients (P<0.001 versus ezetimibe). [9]

Alabama-Specific Prescribing Context

Alabama carries one of the highest age-adjusted cardiovascular mortality rates in the United States. The CDC reports that Alabama's age-adjusted heart disease death rate was 238.8 per 100 to 000 in the most recent year of available data, compared to the national average of 167.1 per 100,000. [10] That gap makes access to effective LDL-C lowering agents like evolocumab a direct public health concern for the state.

Despite that burden, the Alabama Medicaid exclusion and high specialty-tier cost sharing create structural barriers. Telehealth platforms operating in Alabama can help by removing geographic barriers (many rural Alabama counties have few cardiologists or lipid specialists), processing PA documentation efficiently, and connecting patients to manufacturer assistance programs they may not know exist.

Prescribing clinicians in Alabama should note that evolocumab has no required REMS program and no in-office administration requirement. Patients self-administer the 140 mg prefilled SureClick autoinjector subcutaneously every two weeks, or use the Pushtronex on-body infusor for the monthly 420 mg dose. Training takes fewer than ten minutes and is available via video from the manufacturer.